ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Esophageal Cancer in Northeastern Iran

This study is currently recruiting participants.
Verified by National Institutes of Health Clinical Center (CC), December 2007

Sponsored by: National Cancer Institute (NCI)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00450788
  Purpose

Background:

-Esophageal cancer is the most common cancer in Iran's Golestan Province. Nutritional deficiencies, ethnicity and environmental exposures might contribute to the development of this disease.

Objectives:

-To better understand the cause of esophageal cancer in Golestan Province and to reduce its occurrence there.

Eligibility:

-Adults from the Gonbad, Aq-Qala and Kalaleh districts of eastern Golestan Province in Iran.

Design:

  • The study is a collaboration between NIH, the Digestive Disease Research Center of Teheran University of Medical Sciences, and the International Agency for Research on Cancer.
  • Participants complete a lifestyle questionnaire and food frequency questionnaire.
  • Samples of participants' blood, urine, hair and toenail clippings are obtained.

Condition
Esophageal Cancer

MedlinePlus related topics:   Cancer    Esophageal Cancer    Esophagus Disorders   

U.S. FDA Resources

Study Type:   Observational
Study Design:   Other
Official Title:   The Golestan Cohort Study of Esophageal Cancer

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment:   50000
Study Start Date:   March 2007

Detailed Description:

Esophageal cancer is the sixth most common cause of cancer death worldwide, killing over 380,000 people each year. Over 80% of esophageal cancers occur in developing countries, where the great majority of cases are squamous cell carcinomas. Esophageal cancer is characterized by striking geographic variation in incidence. One remarkable high-risk area, called the Central Asian Esophageal Cancer Belt, stretches from the Caspian Sea across Central Asia to northern China and includes focal areas with recorded incidence rates greater than 100/10(5)/ year in both genders. For the past 20 years, DCEG investigators have studied esophageal and gastric cancer in one of these extremely high-risk areas, Linxian, China, at the eastern end of the Belt. While these studies have discovered new risk factors for esophageal cancer in this region, they have produced an incomplete explanation of the etiology of this disease. The Investigators now have the opportunity to perform similar studies in another of these extremely high-risk areas, Golestan Province, Iran, at the other end of the high-risk Belt. The people of Golestan, in northeastern Iran, are geographically, culturally and ethnically quite different from the people of Linxian, and they appear to be similar only in their extraordinarily high rates of esophageal cancer. Performing similar studies in these two exceptional populations will give a better chance to identify important new modifiable risk factors for esophageal cancer in both places.

The proposed cohort study will be collaboration between the Digestive Disease Research Center of Tehran University of Medical Sciences (DDRC), the International Agency for Research on Cancer (IARC), and DCEG. The study will recruit 50,000 adults over four years in three administrative districts of eastern Golestan Province. Baseline assessments will include a lifestyle questionnaire, a semi-quantitative food frequency questionnaire, and collection of blood, hair, nails and urine. Follow-up will include active surveillance by a study team, aided by a comprehensive health network in the rural areas, a GI referral clinic in the largest town, and a provincial cancer registry. The main hypotheses include dietary hypotheses (low consumption of fruits and vegetables, high consumption of hot tea), exposure to potential carcinogens (tobacco, PAHs from non-tobacco sources), novel exposures (opium, animal contact), and genetic susceptibility. The feasibility of this study is demonstrated by the successful completion of a 1,000-person pilot study, the successful recruitment of the first 20,000 subjects in the proposed cohort by DDRC and IARC collaborators, and successful collaboration with the same DDRC and IARC collaborators in an ongoing case-control study and several smaller etiologic studies.

  Eligibility
Ages Eligible for Study:   40 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria
  • Ages 40 to 75

    • Patients with esophogeal cancer
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00450788

Contacts
Contact: Sanford M. Dawsey, M.D.     (301) 594-2930     dawseys@mail.nih.gov    

Locations
France
Interntional Agency for Research on Cancer     Recruiting
      Lyon, France
Iran, Islamic Republic of
Tehran University     Recruiting
      Tehran, Iran, Islamic Republic of

Sponsors and Collaborators
  More Information


Publications:

Study ID Numbers:   999907120, 07-C-N120
First Received:   March 17, 2007
Last Updated:   July 18, 2008
ClinicalTrials.gov Identifier:   NCT00450788
Health Authority:   United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Environmental Risk FactorS  
Genetic Risk Factors  
Genetic Polymorphisms  
Diet
PAH Exposure
Esophageal Cancer

Study placed in the following topic categories:
Digestive System Neoplasms
Digestive System Diseases
Esophageal disorder
Gastrointestinal Diseases
Head and Neck Neoplasms
Esophageal Neoplasms
Gastrointestinal Neoplasms
Esophageal Diseases
Esophageal neoplasm

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on September 19, 2008




Links to all studies - primarily for crawlers